PubMed Review

May 2022

PubMed Review of the Most relevant research on Lung Cancer

SCREENING, DIAGNOSIS, BIOMARKER TESTING, AND STAGING

Lung Cancer: Diagnosis, Treatment Principles, and Screening Am Fam Physician. 2022 May 1;105(5):487-494. Jeffrey Kim  1 , Hobart Lee  1 , Brian W Huang  1

Examining Tobacco Treatment Perceptions and Barriers among Black versus Non-Black Adults Attending Lung Cancer Screening Cancer Prev Res (Phila). 2022 May 3;15(5):327-333. doi: 10.1158/1940-6207.CAPR-21-0398. Krysten W Bold  1 , Sydney Cannon  1 , Bennie B Ford  1 , Susan Neveu  1 , Polly Sather  2 , Benjamin A Toll  1   3 , Lisa M Fucito  1   4   5

Patient Identification of Lung Cancer Screening Follow-Up Recommendations and the Association with Adherence Ann Am Thorac Soc. 2022 May;19(5):799-806. doi: 10.1513/AnnalsATS.202107-887OC. Matthew Triplette  1   2 , David S Wenger  1 , Shahida Shahrir  1 , Erin K Kross  1   3 , Christine Kava  4 , Amanda Phipps  4 , Stephen E Hawes  4 , Allison Cole  5 , Madison Snidarich  2 , Kristina Crothers  1   6

NSCLC SURGERY

Segmentectomy versus wedge resection for radiological solid predominant and low metabolic non-small cell lung cancer Interact Cardiovasc Thorac Surg. 2022 May 2;34(5):814-821. doi: 10.1093/icvts/ivac028. Atsushi Kagimoto  1 , Yasuhiro Tsutani  1 , Takahiro Mimae  1 , Yoshihiro Miyata  1 , Morihito Okada  1

Is surgery worthwhile in locally-advanced NSCLC patients with persistent N2-disease after neoadjuvant therapy? Rev Recent Clin Trials. 2022 May 18. doi: 10.2174/1574887117666220518102321. Online ahead of print. Filippo Lococo  1   2 , Marco Chiappetta  2 , Carolina Sassorossi  2 , et al.

Early discharge on postoperative day 1 following lobectomy for stage I non-small-cell lung cancer is safe in high-volume surgical centres: a national cancer database analysis Eur J Cardiothorac Surg. 2022 May 2;61(5):1022-1029. doi: 10.1093/ejcts/ezab490. Hans E Drawbert  1 , Matthew T Hey  1 , Francisco Tarrazzi  1 , Mark Block  1 , Syed S Razi  1   2

Lobectomy versus segmentectomy in patients with stage T (> 2 cm and ≤ 3 cm) N0M0 non-small cell lung cancer: a propensity score matching study J Cardiothorac Surg. 2022 May 11;17(1):110. doi: 10.1186/s13019-022-01867-x. Linlin Wang #  1 , Lihui Ge #  2 , Sibo You  1 , Yongyu Liu  1 , Yi Ren  3

The impact of segmentectomy versus lobectomy on pulmonary function in patients with non-small-cell lung cancer: a meta-analysis J Cardiothorac Surg. 2022 May 7;17(1):107. doi: 10.1186/s13019-022-01853-3. Yuan Xu #  1 , Yingzhi Qin #  1 , Dongjie Ma  1 , Hongsheng Liu  2

NSCLC – SYSTEMIC THERAPIES (CHEMOTHERAPY, TARGETED THERAPY, AND IMMUNOTHERAPY)

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11. Patrick M Forde  1 , Jonathan Spicer  1 , Shun Lu  1 , et al.

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib JTO Clin Res Rep. 2022 Mar 17;3(5):100311. doi: 10.1016/j.jtocrr.2022.100311. eCollection 2022 May. Yuki Takeyasu  1   2 , Tatsuya Yoshida  1 , Ken Masuda  1 , Yuji Matsumoto  1 , Yuki Shinno  1 , Yusuke Okuma  1 , Yasushi Goto  1 , Hidehito Horinouchi  1 , Noboru Yamamoto  1 , Yuichiro Ohe  1

Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United States Cancer Med. 2022 May 2. doi: 10.1002/cam4.4785. Online ahead of print. Rajwanth Veluswamy  1   2   3 , Fred R Hirsch  2 , Emanuela Taioli  1   3 , Juan Wisnivesky  1   4   5 , Ross Strauss  6 , Douglas Harrough  6 , Boxiong Tang  6 , Gisoo Barnes  6

Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone Thorac Cancer. 2022 May 11. doi: 10.1111/1759-7714.14452. Online ahead of print. Akram Saad  1   2 , Jeffrey Goldstein  3 , Sarit Appel  1   2 , Sameh Daher  1   2 , Damien Urban  1   2 , Amir Onn  1   2 , Hadas Gantz-Sorotsky  1   2 , Anastasiya Lobachov  1 , Teodor Gottfried  1 , Benjamin Spieler  4 , Jair Bar  1   2

Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer Oncologist. 2022 May 6;27(5):407-413. doi: 10.1093/oncolo/oyac021. Christopher A Lemmon  1 , Emily C Zabor  2 , Nathan A Pennell  1

MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer Mol Cancer Res. 2022 May 4;20(5):722-734. doi: 10.1158/1541-7786.MCR-22-0025. Sudarshan R Iyer  1 , Igor Odintsov  2   3 , Adam J Schoenfeld  4 , et al.

Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study BMC Pulm Med. 2022 May 6;22(1):179. doi: 10.1186/s12890-022-01981-5. Wenxian Wang  1   2 , Lan Shao  2   3 , Yibing Xu  2 , Zhengbo Song  2   3 , Guangyuan Lou  2   3 , Yiping Zhang  2   3 , Ming Chen  4

Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse JCO Precis Oncol. 2022 May;6:e2100522. doi: 10.1200/PO.21.00522. Ibiayi Dagogo-Jack  1 , Geoffrey R Oxnard  2 , Makenzi Evangelist  3 , et al.

Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC Drugs. 2022 May;82(7):811-816. doi: 10.1007/s40265-022-01720-4. Epub 2022 May 19. Yahiya Y Syed  1

Treatment Sequencing Strategies in Lung Cancer Zhongguo Fei Ai Za Zhi. 2022 May 20;25(5):323-336. doi: 10.3779/j.issn.1009-3419.2022.104.01. Daniel Humberto Pozza  1 , Ramon Bezerra Andrade de Mello  2

Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer JAMA Netw Open. 2022 May 2;5(5):e2214046. doi: 10.1001/jamanetworkopen.2022.14046. Sanjay Popat  1 , Stephen V Liu  2 , Nicolas Scheuer  3 , Alind Gupta  4 , Grace G Hsu  4 , Sreeram V Ramagopalan  5 , Frank Griesinger  6 , Vivek Subbiah  7

Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis BMC Cancer. 2022 May 7;22(1):514. doi: 10.1186/s12885-022-09592-3. Ziyi Xu #  1 , Chengcheng Liu #  2 , Yixiang Zhu #  1 , Zihua Zou  1 , Tongji Xie  1 , Puyuan Xing  1 , Le Wang  3 , Junling Li  4

Mubritinib enhanced the inhibiting function of cisplatin in lung cancer by interfering with mitochondrial function Thorac Cancer. 2022 May;13(10):1513-1524. doi: 10.1111/1759-7714.14425. Epub 2022 Apr 16. Jingyao Dong  1 , Dongshan Zhu  1 , Mengmeng Chen  1 , Taiwei Wang  1 , Yan Gao  1 , Wei Liu  1

Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung Cancer Clin Drug Investig. 2022 May;42(5):459-464. doi: 10.1007/s40261-022-01145-7. Epub 2022 May 5. Sha Liu #  1 , Tao Pan #  1 , Ming-Kun Wang  1 , Jie Wang  2 , Shuang Zhang  1 , Ping Zhou  3

Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report JTO Clin Res Rep. 2022 Mar 30;3(5):100316. doi: 10.1016/j.jtocrr.2022.100316. eCollection 2022 May. Marie-Hélène Denault  1   2 , Shelley Kuang  1 , Aria Shokoohi  1 , Bonnie Leung  1 , Mitchell Liu  3 , Eric Berthelet  3 , Janessa Laskin  1 , Sophie Sun  1 , Tina Zhang  3 , Barbara Melosky  1 , Cheryl Ho  1

Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer Future Oncol. 2022 May 24. doi: 10.2217/fon-2022-0194. Online ahead of print. Karen L Reckamp  1 , Huamao M Lin  2 , Holly Cranmer  3 , Yanyu Wu  2 , Pingkuan Zhang  2 , Laura J Walton  4 , Stephen Kay  5 , Allie Cichewicz  6 , Binod Neupane  6 , Kyle Fahrbach  6 , Sanjay Popat  7 , D Ross Camidge  8

Trimodality therapy for patients with stage III non-small-cell lung cancer: A comprehensive surveillance, epidemiology, and end results analysis Cancer Treat Res Commun. 2022 May 2;32:100571. doi: 10.1016/j.ctarc.2022.100571. Online ahead of print. Vincent P Grzywacz  1 , Thomas J Quinn  2 , Muayad F Almahariq  2 , Zaid A Siddiqui  3 , Sang W Kim  4 , Thomas M Guerrero  2 , Craig W Stevens  2 , Inga S Grills  2

Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial JTO Clin Res Rep. 2022 Mar 30;3(5):100312. doi: 10.1016/j.jtocrr.2022.100312. eCollection 2022 May. Shengxiang Ren  1 , Jianxing He  2 , Yong Fang  3 , Gongyan Chen  4 , Zhiyong Ma  5 , Jianhua Chen  6 , Renhua Guo  7 , Xiaoyan Lin  8 , Yu Yao  9 , Gang Wu  10 , Quanren Wang  11 , Caicun Zhou  1

NSCLC - RADIOTHERAPY

Prognostic Factors of Survival After Radiotherapy for Lung Cancer-The Impact of Smoking Pack Years In Vivo. May-Jun 2022;36(3):1297-1301. doi: 10.21873/invivo.12830. Elisa M Werner  1 , Esther Glatzel  1 , Sabine Bohnet  2 , Steven E Schild  3 , Dirk Rades  1

Surgical Evaluation in Patients Undergoing Radiation Therapy for Early-stage Lung Cancer Ann Thorac Surg. 2022 May 21;S0003-4975(22)00720-2. doi: 10.1016/j.athoracsur.2022.04.055. Online ahead of print. Marcelo Cerullo, Hui-Jie Lee, Christopher Kelsey, Norma E Farrow, Charles D Scales, Betty C Tong

Repeated Stereotactic Body Radiotherapy for Lung Malignancies: Toxicity Can Be Reduced by Sparing Lung Irradiation Anticancer Res. 2022 May;42(5):2701-2709. doi: 10.21873/anticanres.15748. Shou Watanabe  1 , Hideya Yamazaki  2   3 , Takyua Kimoto  2   3 , Gen Suzuki  2   3 , Kei Yamada  2

Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3) Radiat Oncol. 2022 May 25;17(1):102. doi: 10.1186/s13014-022-02070-x. Sebastian Regnery  1   2   3   4   5 , Jonas Ristau  1   2   3   4 , Fabian Weykamp  1   2   3   4   5 , et al.

Multi-institutional phase II study on the safety and efficacy of dynamic tumor tracking-stereotactic body radiotherapy for lung tumors Radiother Oncol. 2022 May 2;172:18-22. doi: 10.1016/j.radonc.2022.04.028. Online ahead of print. Yukinori Matsuo  1 , Masahiro Hiraoka  2 , Katsuyuki Karasawa  3 , et al.

Causal relation between heart irradiation and survival of lung cancer patients after radiotherapy Radiother Oncol. 2022 May 8;172:126-133. doi: 10.1016/j.radonc.2022.05.002. Online ahead of print. Carsten Brink  1 , Uffe Bernchou  2 , Anders Bertelsen  3 , et al.

SMALL CELL LUNG CANCER - SCLC

The incidences of adverse events in small-cell lung cancer patients after radiotherapy and immunotherapy treatment: a systematic review and meta-analysis Eur Rev Med Pharmacol Sci. 2022 May;26(9):3062-3073. doi: 10.26355/eurrev_202205_28723. Q Wang  1 , A-H Liu, H-J Fan, A-B He, D-D Cao, W Hu, H-L Xu

Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety, and quality of life Curr Med Res Opin. 2022 May 14;1-13. doi: 10.1080/03007995.2022.2078101. Online ahead of print. Rasika Korde  1 , Rajwanth Veluswamy  2   3   4 , Gisoo Barnes  5

Targeting the Ubiquitin-Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer Clin Cancer Res. 2022 May 2;28(9):1966-1978. doi: 10.1158/1078-0432.CCR-21-0344. Safa Majeed  1 , Mansi K Aparnathi  2 , Kevin C J Nixon  2 , et al.

Small Cell Lung Cancer Staging: Prospective Comparison of Conventional Staging Tests, FDG PET/CT, Whole-Body MRI, and Coregistered FDG PET/MRI AJR Am J Roentgenol. 2022 May;218(5):899-908. doi: 10.2214/AJR.21.26868. Epub 2021 Dec 8. Yoshiharu Ohno  1   2   3 , Takeshi Yoshikawa  3   4 , Daisuke Takenaka  4   5 , et al.

Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy Cancer Lett. 2022 May 18;541:215719. doi: 10.1016/j.canlet.2022.215719. Online ahead of print. Yaru Tian  1 , Ji Ma  2 , Xuquan Jing  1 , Xiaoyang Zhai  1 , Yuying Li  1 , Zhijun Guo  3 , Jinming Yu  4 , Hui Zhu  5

PALLIATIVE AND SUPPORTIVE CARE

Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline J Clin Oncol. 2022 May 16;JCO2200687. doi: 10.1200/JCO.22.00687. Online ahead of print. Jennifer A Ligibel  1 , Kari Bohlke  2 , Anne M May  3 , Steven K Clinton  4 , Wendy Demark-Wahnefried  5 , Susan C Gilchrist  6 , Melinda L Irwin  7 , Michele Late  8 , Sami Mansfield  9 , Timothy F Marshall  10 , Jeffrey A Meyerhardt  1 , Cynthia A Thomson  11 , William A Wood  12 , Catherine M Alfano  13

Prolonged administration of aprepitant improves cisplatin-based chemotherapy-induced nausea and vomiting Future Oncol. 2022 May 19. doi: 10.2217/fon-2021-1523. Online ahead of print. Yanying Li  1 , Yu Sun  2 , Bin Liu  3 , Yi Sun  4 , Ping Chen  5 , Ke Xie  6 , Yan Wang  7 , Jiang Zhu  1

Long-term assessment of efficacy with a novel Thoracic Survivorship Program for patients with lung cancer J Thorac Cardiovasc Surg. 2022 May;163(5):1645-1653.e4. doi: 10.1016/j.jtcvs.2021.11.026. Epub 2021 Nov 20 Hari B Keshava  1 , Kay See Tan  2 , Joe Dycoco 1, et al.

Feasibility of Rehabilitation during Chemoradiotherapy among Patients with Stage III Non-Small Cell Lung Cancer: A Proof-of-Concept Study Cancers (Basel). 2022 May 12;14(10):2387. doi: 10.3390/cancers14102387. Melissa J J Voorn  1   2   3 , Bart C Bongers  4   5 , Vivian E M van Kampen-van den Boogaart  6 , Elisabeth J M Driessen  1 , Maryska L G Janssen-Heijnen  1   3

Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors Oncologist. 2022 May 6;27(5):e410-e419. doi: 10.1093/oncolo/oyac056. Tsuyoshi Isawa  1 , Yukihiro Toi  2 , Shunichi Sugawara  2 , Masataka Taguri  3 , Shigeru Toyoda  4

COMPLEMENTARY & ALTERNATIVE THERAPY

Cytotoxic screening and antibacterial activity of Withaferin A J Toxicol Environ Health A. 2022 May 17;1-14. doi: 10.1080/15287394.2022.2071787. Online ahead of print. Altevir Rossato Viana  1 , B Godoy Noro  2 , J C Lenz  2 , M Luiza Machado Teixeira  1 , M Bolson Serafin  3 , R Hörner  3 , C Franco  4 , L Maria Fontanari Krause  5 , B Stefanello Vizzotto  1 , B Jalfim Maraschin  6

MISCELLANEOUS WORKS

Lung Cancer Stem Cells and Their Clinical Implications Cold Spring Harb Perspect Med. 2022 May 17;12(4):a041270. doi: 10.1101/cshperspect.a041270. Samuel P Rowbotham  1   2 , Mounika U L Goruganthu  3 , et al.

Impact of clinical pathways on treatment patterns and outcomes for patients with non-small-cell lung cancer: real-world evidence from a community oncology practice J Comp Eff Res. 2022 Jun;11(8):609-619. doi: 10.2217/cer-2021-0290. Epub 2022 May 12. Natalie R Dickson  1 , Karen D Beauchamp  2 , Toni S Perry  3 , Ashley Roush  1 , Deborah Goldschmidt  4 , Marie Louise Edwards  4 , Laura J Blakely  1

Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC  Natl Compr Canc Netw. 2022 May;20(5):479-487.e2. doi: 10.6004/jnccn.2021.7083. Cary P Gross  1   2 , Craig S Meyer  3 , Sarika Ogale  3 , Matthew Kent  4 , William B Wong  3

Identifying Determinants of Disparities in Lung Cancer Survival Rates from Electronic Health Record Data Stud Health Technol Inform. 2022 May 25;294:715-716. doi: 10.3233/SHTI220567. Wanting Cui 1 , Joseph Finkelstein  1

Long-term exposure to wildfires and cancer incidence in Canada: a population-based observational cohort study Lancet Planet Health. 2022 May;6(5):e400-e409. doi: 10.1016/S2542-5196(22)00067-5. Jill Korsiak  1 , Lauren Pinault  2 , Tanya Christidis  2 , Richard T Burnett  3 , Michal Abrahamowicz  1 , Scott Weichenthal  4

Clinical features of patients with second primary lung cancer following head and neck cancer Ann Thorac Surg. 2022 May 17;S0003-4975(22)00705-6. doi: 10.1016/j.athoracsur.2022.04.052. Online ahead of print. Fumiaki Takatsu  1 , Ken Suzawa  2 , Mikio Okazaki  1 , et al. .

Effect of sponsor on enrollment criteria in non-small cell lung cancer clinical trials J Cancer Policy. 2022 May 20;100336. doi: 10.1016/j.jcpo.2022.100336. Online ahead of print. Ryan A Cooper  1 , Yan Chai  2 , Jorge Nieva  3

Prospective Comparative Effectiveness Trial of Multidisciplinary Lung Cancer Care Within a Community-Based Health Care System JCO Oncol Pract. 2022 May 24;OP2100815. doi: 10.1200/OP.21.00815. Online ahead of print. Matthew P Smeltzer  1 , Meredith A Ray  1 , Nicholas R Faris  2 , et al.

Cancer Epidemiology in Hispanic Populations: What Have We Learned and Where Do We Need to Make Progress? Cancer Epidemiol Biomarkers Prev. 2022 May 4;31(5):932-941. doi: 10.1158/1055-9965.EPI-21-1303. Laura Fejerman  1 , Amelie G Ramirez  2 , Anna María Nápoles  3 , Scarlett Lin Gomez  4 , Mariana C Stern  5

Improving Sexual and Gender Minority Cancer Care: Patient and Caregiver Perspectives From a Multi-Methods Pilot Study Front Oncol. 2022 May 6;12:833195. doi: 10.3389/fonc.2022.833195. eCollection 2022. Miria Kano  1   2 , Shoshana Adler Jaffe  2 , Stephanie Rieder  2   3 , et al.

Archives